Navigation Links
Pharmacopeia Initiates Second Phase 2 Hypertension Study with PS433540 (DARA)
Date:3/3/2008

Phase 2b Trial to Examine Safety and Efficacy of DARA versus Active Control

PRINCETON, N.J., March 3 /PRNewswire-FirstCall/ -- Pharmacopeia (Nasdaq: PCOP), an innovator in the discovery and development of novel small molecule therapeutics, today announced the initiation of a Phase 2b clinical study of PS433540, the company's lead internal product candidate. This randomized, double-blind, placebo and active-controlled, parallel-group study is designed to evaluate the compound's safety and efficacy at three different doses in subjects with Stage 1 and Stage 2 hypertension.

After a lead-in period, the multi-center trial is expected to randomize approximately 375 subjects into five study arms receiving PS433540 (200 mg, 400 mg or 800 mg); irbesartan (300 mg), an angiotensin II receptor antagonist; or placebo. All doses will be administered once daily for 12 weeks. The trial's primary objective is to compare the change from baseline in mean seated systolic blood pressure for each dose of PS433540 with placebo. Additional study objectives include comparisons of changes in blood pressure for each dose of PS433540 with irbesartan.

"We are pleased with the DARA program's rapid progress. This is our second Phase 2 study of PS433540 in hypertensive patients to provide key indications of the compound's therapeutic potential," said Les Browne, Ph.D., President and Chief Executive Officer of Pharmacopeia. "We look forward to the completion of this study by the end of 2008 as well as the reporting of results from our on-going Phase 2a trial in the second quarter of 2008."

Pharmacopeia recently completed enrollment in its ongoing Phase 2a trial of PS433540 in patients with Stage 1 and Stage 2 hypertension. Results from that study
'/>"/>

SOURCE Pharmacopeia
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Pharmacopeia Completes Enrollment in Phase 2 Hypertension Study with PS433540 (DARA)
2. Pharmacopeia Nominates Novel Chemokine Receptor Antagonist for Development
3. Pharmacopeia to Present at BIO CEO & Investor Conference 2008
4. Pharmacopeia Announces Additional Positive Findings from Phase 1 Multiple Ascending Dose Study of PS433540 (DARA)
5. Pharmacopeia Announces Third Quarter 2007 Financial Results
6. Pharmacopeia Earns Milestone Payment From Schering-Plough on Initiation of Phase 1 Clinical Trials of Novel Therapeutic Candidate
7. Phase 2 Clinical Studies Initiated for a Novel Therapeutic Candidate Identified Through Pharmacopeia Collaboration
8. Pharmacopeia Initiates Phase 2 Hypertension Study with PS433540 (DARA)
9. Pharmacopeia Announces Positive Results from Phase 1 Multiple Ascending Dose Study of PS433540 (DARA)
10. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
11. Phosphagenics Initiates U.S. Clinical Trials for Its Topical Retinoic Acid
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... 31, 2015 Quietly, sedately, Morocco,s ... the domestic pharmaceutical industry is strong, with a well-developed ... high international standards. One place where the ... sub-Saharan Africa: Morocco has quietly become the second largest ... Africa . Indeed, Moroccan pharma companies have been ...
(Date:7/31/2015)... , July 31, 2015 ... Analyzers Market by Product (Bioimpedance Analyzers (BIA), Dual-Energy X-ray ... Hydrostatic Weighing) - Global Analysis & Forecast to 2019", ... was pegged at $911.1 Million 2014 and is estimated ... a CAGR of 9.4% from 2014 to 2019. ...
(Date:7/30/2015)... , July 30, 2015 IRIDEX Corporation ... release its second quarter 2015 financial results after the ... In conjunction with the release, the Company will host ... 5:00 p.m. Eastern Time on Thursday, August ... quarter and other business developments. Interested parties ...
Breaking Medicine Technology:PharmaBoardroom Releases New Morocco Pharmaceuticals Report 2PharmaBoardroom Releases New Morocco Pharmaceuticals Report 3Body Composition Analyzers Market Worth $1,425.7 Million by 2019 2Body Composition Analyzers Market Worth $1,425.7 Million by 2019 3Body Composition Analyzers Market Worth $1,425.7 Million by 2019 4IRIDEX Announces Second Quarter 2015 Conference Call and Release Date 2
... May 25, 2012  ... and Multilab Indústria e Comércio de Produtos Farmacêuticos ... jointly announced that both parties have signed an ... Brazil, "Takeda Brazil"), a wholly-owned subsidiary of Takeda, ...
... 2012  The National Organization for Rare Disorders (NORD) applauds legislation ... the Food and Drug Administration Safety & Innovation Act ... the most comprehensive improvements to public policy for rare disease ... . (Logo: http://photos.prnewswire.com/prnh/20110719/DC37656LOGO-b ) ...
Cached Medicine Technology:Takeda to Acquire Multilab, Enhancing its Business Infrastructure in Brazil 2Takeda to Acquire Multilab, Enhancing its Business Infrastructure in Brazil 3Takeda to Acquire Multilab, Enhancing its Business Infrastructure in Brazil 4NORD Calls Senate Bill Most Important Since Orphan Drug Act 2
(Date:7/31/2015)... ... July 31, 2015 , ... Precision Aesthetics is New York’s only Thermage ... also the first provider of Exilis non-surgical fat reduction in New York. Due ... attracted a large International clientele. Many patients travel to New York to get ...
(Date:7/31/2015)... ... July 31, 2015 , ... The 2nd annual Ride to Fight On ... on October 3, 2015. The Ride to Fight On is a cycling fundraiser that ... Healthcare, The West Clinic and The University of Tennessee Health Science Center. A health ...
(Date:7/31/2015)... ... 31, 2015 , ... Jacksonville-based drug and alcohol rehabilitation center, ... Center. The medical community, social workers, law enforcement, and government officials are all ... the effort to better understand and combat sex trafficking. Lead by sex trafficking ...
(Date:7/31/2015)... ... July 31, 2015 , ... M3 USA MDLinx.com, source of the ... new Board Exam Courses. , The additions of Gastroenterology, Pulmonology and Allergy/Immunology round ... MDLinx makes preparing for the exam easy and painless. MDLinx offers thousands of ...
(Date:7/31/2015)... ... July 31, 2015 , ... According to an ... gathered to see if they could reach a consensus on the steps that need ... facelifts. Overall, the group reached 90 percent consensus on a series of steps that ...
Breaking Medicine News(10 mins):Health News:West Cancer Center Announces 2nd Annual Ride to Fight On 2Health News:West Cancer Center Announces 2nd Annual Ride to Fight On 3Health News:Lakeview Health Links Sex Trafficking and Addiction in Special Jacksonville Educational Workshop 2Health News:Lakeview Health Links Sex Trafficking and Addiction in Special Jacksonville Educational Workshop 3Health News:MDLinx Offers Three New Board Exam Prep Courses - Gastroenterology, Pulmonology and Allergy/Immunology 2Health News:MDLinx Offers Three New Board Exam Prep Courses - Gastroenterology, Pulmonology and Allergy/Immunology 3Health News:Article on Plastic Surgery Consensus Highlights the Duties of Veteran Plastic Surgeons, says Beverly Hills Physicians 2Health News:Article on Plastic Surgery Consensus Highlights the Duties of Veteran Plastic Surgeons, says Beverly Hills Physicians 3
... ... teach participants unique personal marketing strategies to find employment with a six-point system “The ... is a former talk show host in Columbia at WVOC 560 AM; Kenneth Shuler ... be held for Thomas providing free career counseling services , ...
... ... infection 33 times greater than that reported for our accredited ambulatory surgery centers. ... (PRWEB) June 18, ... Schaefer, Michael Jhung et al (JAMA 2010;303(22):2273 - 2279) correctly places emphasis on the ...
... disorder affecting one in 100 people worldwide. Most cases aren,t ... hallucinations as a teenager or adult. By that time, the ... difficult to treat. In a paper published recently online ... the University of North Carolina at Chapel Hill and Columbia ...
... The National Heart, Lung, and Blood Institute (NHLBI), part of ... to determine if the safety and efficacy of red blood ... been stored. One of the grants supports the first large, ... patients who receive transfusions of red blood cells that have ...
... ... to help women restore energy, passion and healthy hormonal balance. , ... Tampa, FL (Vocus) June 21, 2010 ... supplement for women. Dan-e™ is made of a patent-pending blend of Pro-Hormones and vital ...
... University of Leicester and the University of Ferrara in Italy ... to relieve cancer pain without causing many of the side ... show that 90% of cancer patients experience pain in the ... problem. Currently, the use of drugs like morphine produces side ...
Cached Medicine News:Health News:Columbia Extreme Job Makeover Slated for June 26 2Health News:Columbia Extreme Job Makeover Slated for June 26 3Health News:Infection Rate in Accredited Ambulatory Facilities is Lower than in Hospitals 2Health News:Brain signs of schizophrenia found in babies 2Health News:NHLBI funds research to improve safety of red blood cell transfusions 2Health News:NHLBI funds research to improve safety of red blood cell transfusions 3Health News:NHLBI funds research to improve safety of red blood cell transfusions 4Health News:NHLBI funds research to improve safety of red blood cell transfusions 5Health News:NHLBI funds research to improve safety of red blood cell transfusions 6Health News:NHLBI funds research to improve safety of red blood cell transfusions 7Health News:World Renowned Physician Launches Dan-e™ All-Natural Nutritional Supplement for Women 2Health News:New drugs to relieve cancer pain 2
... D15/810 diode laser is a versatile and ... soft tissue applications. With excellent hemostatic and ... flexible fiber optic delivery system that allows ... environments alike.,Compact and portable, the Ceralas D15/810 ...
... II is a monoclonal antibody based ... identification of Neisseria gonorrhoeae. The test ... run with no heating or pretreatment. ... viable or fresh cultures. GonoGen&trade II ...
The One-Step Gonorrhea Antigen Tests are qualitative immunoassays for detecting the Gonorrhea Antigen (NGH) in secretory products (swab)....
... thermal keratoplasty (LTK). This procedure was FDA ... reduction of hyperopia from +0.75 to +2.50 diopters ... to 0.75 diopters of astigmatism and refractive stability ... refractive surgery, LTK is not performed in an ...
Medicine Products: